Fen Phen® is manufactured by Interneuron Pharmaceuticals and prescribed to morbidly obese patients for weight loss. However, it was quickly taken off the market due to deadly side effects. Fen-Phen® is fenfluramine and phentermine combined together. The use of one drug without the other proved no weight loss; therefore, the drug was developed together resulting in rapid weight loss in patients. Combining the two drugs proved to regulate specific parts of the brain. Fenfluramine focuses has an affect on mood and appetite, and phentermine further focused on appetite control and warding off brain signals to overeat.
Fen Phen® was proven by experts to lead to improper functioning of the mitral valve, the valve in the heart located between the left atrium and left ventricle, which helps control the flow of blood. Furthermore, Fen Phen® put obese patients at serious risk of developing primary pulmonary hypertension PPH. This is a dangerous increase in blood pressure occurring in the pulmonary artery, vein, or capillaries. Symptoms of PPH include shortness of breath with or without activity, hyperventilating, blood in sputum, and blue lips or blue feet (cyanosis).